| Sample number . | Age/ sex . | Diagnosis . | Sample type . | Molecular . | Chromosomal abnormalities . | Fold change in IL1RAP MFI (relative to isotype) . |
|---|---|---|---|---|---|---|
| MDS01 | 60/M | High risk MDS | PB | N/A | Monosomy 7 | 5.9 |
| MDS02 | N/A | High risk MDS | PB | N/A | Monosomy 7 | 7.1 |
| AML01 | 76/M | AML M4, myelomonocytic | BM | U2AF1 S34F; TET2 frameshift & C1378Y & D1587G; ASXL1 L1304V; NRAS G13D | None detected | 10.4 |
| AML02 | 68/M | Residual AML after induction therapy with monocytic differentiation; history of MPD, DLBCL | PB | JAK2; SRSF2 P95H; TET2 R550X; TP53 R175H | Complex cytogenetics & t(4:11) | 6.1 |
| AML03 | M | High risk MDS/AML | PB | N/A | del(13)(q12q22) and der(18)t(13;18)(q22;q23) | 11.8 |
| AML04 | 25/M | AML M2 | BM | FLT3-ITD | Trisomy 8 | 4.4 |
| AML05 | 62/F | AML/MPN | PB | JAK2 V617F; TP53 R248W; IDH2 R140Q | None detected | 5.9 |
| AML06 | 49/F | Relapsed AML | PB | FLT3-ITD | 46,XX | 29 |
| AML07 | 73/M | AML | PB | N/A | 46,XY,t(1;4)(p21;q21)[3]/ 46,XY[7] | 4.1 |
| AML08 | 70/M | AML (monocytic) | PB | ASXL1 L823* (nonsense); BCOR R1183*; RUNX1 frameshift; SRSF2 P95H; TET2 insertion & R1516* | None detected | 10.3 |
| AML09 | 54/F | AML (monocytic) | PB | FLT3-TKD; DNMT3A R882H; IDH1 R132H; MLL-PTD | None detected | 22 |
| AML10 | 61/F | AML M5 with hyperleucocytosis | BM | FLT3-ITD; DNMT3A R882H; NPM1 frameshift | None detected | 12 |
| AML11 | 48/F | AML (monocytic) | PB | CEBPA frameshift; CSF3R R698H; NF1 SNP | None detected | 2.5 |
| AML12 | 37/F | AML | PB | FLT3-ITD | 47,XX,+8[15]/ 46,XX[5] 21–24% trisomy 8 (D8Z2,RUNX1T1)x3[42-48/200] | 1.9 |
| AML13 | 67/M | AML | PB | MLL-PTD | Trisomy 8 | 13.2 |
| AML14 | 59/F | AML | PB | FLT3-ITD; NPM1; WT1 | None detected | 3.1 |
| AML15 | 38/M | AML | PB | NRAS | 46,XY t(9;11)(p22;q23) | 3.6 |
| AML16 | 54/M | AML | PB | DNMT3A, NPM1 | None detected | 12.7 |
| AML17 | 38/M | AML | PB | N/A | N/A | 8.3 |
| AML18 | 29/M | AML | BM | None detected | t(8;21)(q22;q22) 45,X,-Y,t(8;21)(q22;q22)[20] | 19.4 |
| AML19 | 61/M | MDS/MPN/AML | PB | JAK2 | 46,XY,der(8) ?t(8;21)(q22;q22), del(9)(q13q22), dup(12)(q14q24.1), -22,+1-2mar[8]/46,xy(3) | N/A |
| Sample number . | Age/ sex . | Diagnosis . | Sample type . | Molecular . | Chromosomal abnormalities . | Fold change in IL1RAP MFI (relative to isotype) . |
|---|---|---|---|---|---|---|
| MDS01 | 60/M | High risk MDS | PB | N/A | Monosomy 7 | 5.9 |
| MDS02 | N/A | High risk MDS | PB | N/A | Monosomy 7 | 7.1 |
| AML01 | 76/M | AML M4, myelomonocytic | BM | U2AF1 S34F; TET2 frameshift & C1378Y & D1587G; ASXL1 L1304V; NRAS G13D | None detected | 10.4 |
| AML02 | 68/M | Residual AML after induction therapy with monocytic differentiation; history of MPD, DLBCL | PB | JAK2; SRSF2 P95H; TET2 R550X; TP53 R175H | Complex cytogenetics & t(4:11) | 6.1 |
| AML03 | M | High risk MDS/AML | PB | N/A | del(13)(q12q22) and der(18)t(13;18)(q22;q23) | 11.8 |
| AML04 | 25/M | AML M2 | BM | FLT3-ITD | Trisomy 8 | 4.4 |
| AML05 | 62/F | AML/MPN | PB | JAK2 V617F; TP53 R248W; IDH2 R140Q | None detected | 5.9 |
| AML06 | 49/F | Relapsed AML | PB | FLT3-ITD | 46,XX | 29 |
| AML07 | 73/M | AML | PB | N/A | 46,XY,t(1;4)(p21;q21)[3]/ 46,XY[7] | 4.1 |
| AML08 | 70/M | AML (monocytic) | PB | ASXL1 L823* (nonsense); BCOR R1183*; RUNX1 frameshift; SRSF2 P95H; TET2 insertion & R1516* | None detected | 10.3 |
| AML09 | 54/F | AML (monocytic) | PB | FLT3-TKD; DNMT3A R882H; IDH1 R132H; MLL-PTD | None detected | 22 |
| AML10 | 61/F | AML M5 with hyperleucocytosis | BM | FLT3-ITD; DNMT3A R882H; NPM1 frameshift | None detected | 12 |
| AML11 | 48/F | AML (monocytic) | PB | CEBPA frameshift; CSF3R R698H; NF1 SNP | None detected | 2.5 |
| AML12 | 37/F | AML | PB | FLT3-ITD | 47,XX,+8[15]/ 46,XX[5] 21–24% trisomy 8 (D8Z2,RUNX1T1)x3[42-48/200] | 1.9 |
| AML13 | 67/M | AML | PB | MLL-PTD | Trisomy 8 | 13.2 |
| AML14 | 59/F | AML | PB | FLT3-ITD; NPM1; WT1 | None detected | 3.1 |
| AML15 | 38/M | AML | PB | NRAS | 46,XY t(9;11)(p22;q23) | 3.6 |
| AML16 | 54/M | AML | PB | DNMT3A, NPM1 | None detected | 12.7 |
| AML17 | 38/M | AML | PB | N/A | N/A | 8.3 |
| AML18 | 29/M | AML | BM | None detected | t(8;21)(q22;q22) 45,X,-Y,t(8;21)(q22;q22)[20] | 19.4 |
| AML19 | 61/M | MDS/MPN/AML | PB | JAK2 | 46,XY,der(8) ?t(8;21)(q22;q22), del(9)(q13q22), dup(12)(q14q24.1), -22,+1-2mar[8]/46,xy(3) | N/A |
Age, sex, diagnosis, sample type, molecular abnormalities, chromosomal abnormalities (fluorescence in situ hybridization, karyotyping), and IL1RAP expression (fold change in MFI relative to isotype control antibody stain) are shown where data were available. * indicates stop codon.